Loftus EV Jr.Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology . 2004;126:1504-1517.
2.
Kishikawa H. , Nishida J., Nakano M., Hirano E., Morishita T., Ishii H.Ulcerative colitis associated with aplastic anemia. Dig Dis Sci. 2003;48:1376-1379.
3.
Sharma BC, Yachha SK, Mishra RN, Gupta D.Hypoplastic anemia associated with ulcerative colitis in a child. J Pediatr Gastroenterol Nutr. 1996;23:326-328.
4.
Sandborn WJA review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol . 1996;91:423-433.
5.
de Boer NK, Derijks LJ, Gilissen LP, et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol. 2005;11:5540-5544.
6.
Kirschner BSSafety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology . 1998;115:813-821.
Gearry RB, Barclay MLAzathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20: 1149-1157.
9.
Frohman EM, Havrdova E., Levinson B., Slanar O.Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. Mult Scler. 2006;12:108-111.
10.
Present DH, Meltzer SJ, Krumholz MP, Wolke A., Korelitz BI6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
11.
Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JEBone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34: 1081-1085.
12.
Bernstein CN , Artinian L., Anton PA, Shanahan F.Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci. 1994;39:1638-1641.
13.
Colombel JF , Ferrari N., Debuysere H., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000 ;118:1025-1030.
14.
Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RNNormal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000;30:409-413.
15.
Sies C., Florkowski C., George P., et al. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. N Z Med J.2005;118:U1324.
16.
Kotanagi H. , Ito M., Koyama K., Chiba M.Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn’s disease. J Gastroenterol . 1998;33:571-574.
17.
Casellas, F. , Vallano A., Malagelada JRLeukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories. J Clin Gastroenterol. 1996;22:160-161.
de Boer NK, Wong DR, Jharap B., et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102:2747-2753.
20.
Dewit O., Vanheuverzwyn R., Desager JP, Horsmans Y.Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther . 2002;16:79-85.
21.
Szumlanski CL, Weinshilboum RMSulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine . Br J Clin Pharmacol. 1995;39: 456-459.
22.
Lewis LD, Benin A., Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997;62:464-475.
